AR882 + allopurinol

AR882 + allopurinol is a combination therapy under investigation for the treatment of gout and tophaceous gout. AR882 is a novel, potent, and selective uric acid transporter 1 (URAT1) inhibitor that blocks the reabsorption of uric acid in the renal tubules, thereby increasing its excretion in urine. Allopurinol is a well-established xanthine oxidase inhibitor that reduces uric acid production. Clinical studies have shown that combining AR882 with allopurinol results in greater serum urate lowering than either agent alone, with additive effects observed. The combination has demonstrated robust efficacy and favorable safety profiles in clinical trials for patients with gout, including those with advanced disease or renal impairment[8][1][2].

Other names

none